JY
NGNE icon

Jeff Yass’s Neurogene NGNE Stock Holding History

Jeff Yass’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Sell
92,400
-33,500
-27% -$922K ﹤0.01% 5695
2026
Q1 		$2.54M Buy
125,900
+115,900
+1,159% +$2.25M ﹤0.01% 5631
2025
Q4 		$206K Sell
10,000
-13,300
-57% -$331K ﹤0.01% 10813
2025
Q3 		$404K Sell
23,300
-70,900
-75% -$1.42M ﹤0.01% 9453
2025
Q2 		$1.41M Buy
94,200
+50,500
+116% +$792K ﹤0.01% 6603
2025
Q1 		$512K Buy
43,700
+24,700
+130% +$429K ﹤0.01% 8855
2024
Q4 		$434K Buy
+19,000
New +$707K ﹤0.01% 9024
2023
Q3 		– Sell
-710
Closed -$11.8K – 12632
2023
Q2 		$11.8K Buy
+710
New +$11.6K ﹤0.01% 11735
2022
Q3 		– Sell
-2,870
Closed -$59K – 13805
2022
Q2 		$59K Sell
2,870
-1,550
-35% -$37.8K ﹤0.01% 11875
2022
Q1 		$166K Sell
4,420
-265
-6% -$15.5K ﹤0.01% 11458
2021
Q4 		$452K Buy
4,685
+2,890
+161% +$352K ﹤0.01% 9469
2021
Q3 		$260K Buy
1,795
+130
+8% +$19.9K ﹤0.01% 10926
2021
Q2 		$307K Sell
1,665
-250
-13% -$55.3K ﹤0.01% 10730
2021
Q1 		$471K Sell
1,915
-300
-14% -$76.7K ﹤0.01% 9620
2020
Q4 		$625K Buy
2,215
+1,600
+260% +$391K ﹤0.01% 7796
2020
Q3 		$148K Buy
+615
New +$149K ﹤0.01% 9695
2020
Q2 		– Sell
-1,415
Closed -$322K – 10649
2020
Q1 		$322K Sell
1,415
-600
-30% -$123K ﹤0.01% 7841
2019
Q4 		$496K Buy
+2,015
New +$201K ﹤0.01% 6998
2018
Q3 		– Sell
-1,045
Closed -$55K – 9901
2018
Q2 		$55K Buy
+1,045
New +$272K ﹤0.01% 9248
2017
Q3 		– Sell
-500
Closed -$141K – 9355
2017
Q2 		$141K Sell
500
-695
-58% -$199K ﹤0.01% 8526
2017
Q1 		$399K Sell
1,195
-245
-17% -$86.1K ﹤0.01% 6895
2016
Q4 		$475K Sell
1,440
-1,545
-52% -$415K ﹤0.01% 7101
2016
Q3 		$798K Buy
+2,985
New +$602K ﹤0.01% 5213

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Jeff Yass's NGNE Position: Q3 2025 in Review

Jeff Yass sold out of Neurogene (NGNE) in Q3 2025, closing a stake of 26,006 shares — an estimated $522K sold.

Jeff Yass first reported a position in NGNE in Q2 2016 and held it in 20 quarters. The position peaked at $6.68M in Q1 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

  • Jeff Yass reported no remaining Neurogene position as of Q3 2025 after selling out during the quarter.
  • Jeff Yass sold 26,006 Neurogene shares in Q3 2025, an estimated $522K.
  • Jeff Yass first reported a position in Neurogene in Q2 2016 and held it in 20 quarters.
  • Jeff Yass's Neurogene position peaked at $6.68M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.